202TiP ASTEFANIA: A phase III study of trastuzumab emtansine (T-DM1) plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy.

Authors :: Schmid, P.
Bachelot, T.
Bianchini, G.
Harbeck, N.
Loi, S.
Park, Y.H.
Prat, A.
Gilham, L.
Boulet, T.
Gochitashvili, N.
Monturus, E.
Lambertini, C.
Nyawira, B.
Knott, A.
Hurvitz, S.A.
Source :: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS445-S446. 2p.
Publication Year :: 2021

Subjects :: *CANCER invasiveness
*BREAST cancer
*ATEZOLIZUMAB
*TRASTUZUMAB
*PLACEBOS

Full Text Access

Tools